Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
International Journal of Clinical Pharmacy · 2025
DOI: 10.1007/s11096-025-01912-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Hanrui Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Rituximab, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The CD20 × CD3 bispecific antibody glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) has demonstrated clinical efficacy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). AIM: The aim of this study was to evaluate the cost-effectiveness of Glofit-GemOx versus R-GemOx for relapsed or refractory DLBCL patients following one or more previous lines of therapy from the perspective of healthcare in China. METHOD: A three-state partitioned survival model was constructed based on the STARGLO study to assess the cost-effectiveness of Glofit-GemOx versus rituximab-GemOx (R-GemOx). Quality-adjusted life years (QALYs) were used as health outcomes, and the incremental cost-effectiveness ratio (ICER) was calculated. One-way deterministic sensitivity analyses and probabilistic sensitivity analyses were performed on key parameters to assess the robustness of the base analysis results. RESULTS: The costs in Glofit-GemOx regimen were $266,518.83, whereas the costs of R-GemOx regimen were $43,227.09. Compared with the R-GemOx regimen, the Glofit-GemOx regimen resulted in an increase of 0.85 QALYs, yielding an ICER of $262,696.16 per QALY. The ICER significantly exceeded the willingness-to-pay (WTP) threshold of $38,188/QALY and sensitivity analysis revealed the cost of glofitamab had a substantial effect on results. CONCLUSION: Compared with R-GemOx, Glofit-GemOx is not cost-effective compared for relapsed or refractory DLBCL patients in China at current price. A negotiated price reduction for glofitamab could substantially improve its cost-effectiveness profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
- Department of Pharmacy, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China. huming@scu.edu.cn.
Zitieren
APA
Zheng, H., Zou, L., & Hu, M. (2025). Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-025-01912-4
Vancouver
Zheng H, Zou L, Hu M. Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-025-01912-4
BibTeX
@article{Zheng2025,
author = {Zheng, Hanrui and Zou, Linke and Hu, Ming},
title = {Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
doi = {10.1007/s11096-025-01912-4}
}
EUVIMED